The U.S. Food and Drug Administration (FDA) will hold a two-day advisory committee meeting on July 23 and 24 to evaluate ...

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus ("LyoGenesis"), a cGMP ...

The uncommitted facility provides Hims with a working-capital tool as it scales its healthcare and pharmacy operations.

Kennedy Jr.'s recent push to expand access to peptides, FDA career scientists determined there isn't adequate evidence to support any of the ones under consideration for production by compounding ...

The FDA has listed its advisory members for the committee that will discuss peptides in late July. Owais Durrani, DO, an emergency medicine physician in Houston, previously wrote for Healio that “some ...

The stock is already showing accelerating fundamentals (33% LTM revenue growth, 73% gross margin) plus credible weight-loss distribution via Novo Nordisk’s largest telehealth partner. The market is ...

U.S. FDA staff ​reviewers said there is little evidence to allow compounding pharmacies to manufacture seven popular peptides ...

The FDA staff’s view clashes with RFK Jr.’s push to deregulate peptides and move more of them toward Category 1 status.

The health secretary has advocated for deregulating certain peptides, but FDA scientists point to a lack of data about their ...